To the Editor: There is a growing body of evidence that sodium-glucose co-transporter 2
(SGLT2) inhibition may confer a renoprotective effect. This beneficial renal effect is thought …

Aims Blood uric acid (UA) levels are frequently elevated in patients with heart failure and
reduced ejection fraction (HFrEF), may lead to gout and are associated with worse …

Background Chronic kidney disease and heart failure are insulin resistant states associated
with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

Graphical Abstract Effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients
with chronic kidney disease (CKD) or heart failure with reduced ejection fraction (HFrEF) …

Abstract Background and Aims Chronic kidney disease (CKD) is a chronic and progressive
disease which imposes a significant burden on patients and healthcare systems as the …

Introduction Sodium-dependent glucose cotransporter 2 (SGLT2) is a glucose transporter
expressed on the proximal tubular cells, where it reabsorbs glucose from the glomerular …

Aims To evaluate comprehensively the safety of dapagliflozin in patients with type 2
diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium …

A treatment option for patients with type 2 diabetes mellitus (T2DM) is inhibition of the
sodium-glucose cotransporter 2 (SGLT2). Using this therapy, improvement in glycaemic …

Abstract Background and Aims Sodium–glucose cotransporter 2 inhibitors decrease blood
pressure in patients with type 2 diabetes, but the consistency and magnitude of blood …